Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of Sanqi panax notoginseng to preparation of medicine for preventing or treating deep vein thrombosis

A technology for deep vein thrombosis and preparation of drugs, which is applied in the field of clinical pharmacy, can solve problems such as increased bleeding risk, bleeding tendency, and use restrictions, and achieve the effects of safe clinical medication, good prevention and treatment, and less toxic and side effects

Inactive Publication Date: 2017-08-18
HARBIN ZHENBAO PHARMA +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There are even fewer clinical drugs for the prevention and treatment of deep vein thrombosis. The main drugs are unfractionated heparin, low molecular weight heparin, Xa factor inhibitors, and vitamin K antagonists. The guidelines for the prevention of venous thromboembolism specifically suggest that patients at risk of bleeding should weigh the pros and cons of preventing lower extremity deep vein thrombosis and increasing the risk of bleeding

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Prevention plan and effect of deep vein thrombosis sequelae after orthopedic lower extremity surgery

[0027] 1. Method

[0028] (1) Method of administration

[0029] 1) Medication cycle: medication for 14 days, follow-up for 30 days.

[0030] 2) Randomly select 50 patients with lower extremity fractures in the department of orthopedics as research objects. The average age of the patients is 37 years (18-59 years), including 31 males and 19 females. They are randomly divided into control group and prevention group, with 25 patients in each group example.

[0031]Basic preventive measures for the control group and the prevention group: the surgical operation should be as gentle and precise as possible to avoid damage to the venous intima; the tourniquet should be used in a standardized manner; the affected limb should be raised after surgery to prevent deep venous reflux disorders; routine venous thrombosis knowledge education should be carried out to encoura...

Embodiment 2

[0037] Example 2 Therapeutic method and effect of deep vein thrombosis sequelae after orthopedic lower extremity surgery

[0038] 1. Method

[0039] The diagnostic criteria for deep vein thrombosis sequelae after orthopedic lower extremity surgery are one of the following symptoms: soreness of the affected limb, chronic edema, skin pigmentation, stasis dermatitis, ulcer, superficial vein dilatation or varicose.

[0040] Selected cases: 69 patients who met the diagnostic criteria for deep vein thrombosis sequelae after orthopedic lower extremity surgery, half to three months after surgery, with an average age of 38 years (19-62 years), including 37 males and 32 females.

[0041] Treatment plan: Selected cases were given Xuesaitong for injection 600mg added to 500mL of 5% glucose injection intravenously, 40 drops / min, 1 time / day, and the curative effect was observed after 14 days of medication.

[0042] Efficacy standard: According to the three-level standard to judge the curat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of Sanqi panax notoginseng to preparation of a medicine for preventing or treating deep vein thrombosis. The application finds out that the Sanqi panax notoginseng medicine has very good prevention and treatment effects on deep vein thrombosis sequela; meanwhile, hemorrhagic symptoms caused by medicines including heparin and the like are also avoided; an anticoagulant does not need to be additionally given to a patient and effective treatment can be given to the patient. The Sanqi panax notoginseng provided by the invention is safe in a clinical medication process; the Sanqi panax notoginseng for injection has a remarkable curative effect on prevention and treatment of the deep vein thrombosis sequela after surgeries.

Description

technical field [0001] The present invention relates to the field of clinical pharmacy, in particular to a new application of a known Xuesaitong drug for preventing or treating deep vein thrombosis in patients with orthopedic diseases. Background technique [0002] Deep vein thrombosis (DVT) refers to the abnormal coagulation of blood in deep veins, which is a disorder of venous return in the lower extremities. Thrombosis usually occurs in a state of immobilization, such as after major orthopedic surgery. The pathogenic factors include slow blood flow, venous wall damage and hypercoagulable state. After thrombosis, except for a few that can ablate on their own or are limited to the site of occurrence, most of them will spread to the deep vein trunk of the whole limb. If not diagnosed and treated in time, most of them will develop into sequelae of thrombosis, which will affect the quality of life of patients for a long time ; Some patients may be complicated by pulmonary emb...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/258A61P9/14A61P17/02A61P7/10A61P17/00
CPCA61K36/258A61K9/0019
Inventor 方同华崔玉海周广红范玉奇贾文娟王丽王博
Owner HARBIN ZHENBAO PHARMA